Beacon Biosignals Expands Series B Financing to $97M

Beacon Biosignals has announced an extension of its Series B financing, adding new investors including JSL Health, Palo Santo VC, Kicker Ventures, and Samsung Next. The round now totals $97 million, bringing the company’s cumulative funding to more than $132 million. The new capital will be used to support its efforts to advance brain health through scalable, at-home EEG and data analytics for diagnostics, clinical trials, and precision medicine.

The latest funding builds on the company’s previously disclosed $86 million Series B round, which was led by a group of healthcare and technology investors such as Innoviva, GV (Google Ventures), S32, Catalio Capital Management, General Catalyst, Logos Capital, Casdin Capital, and Indicator Ventures.

“This milestone reflects strong momentum behind our vision to make brain health measurable, scalable, and actionable,” said Jacob Donoghue, CEO of Beacon Biosignals. “We’re grateful for the support of our new and existing investors as we build the future of brain health.”

“Beacon is uniquely positioned to unlock the potential of brain data at scale,” said Daniel Goldberg, Managing Director at Palo Santo. “Their combination of clinical-grade EEG and advanced analytics is enabling a new era of discovery and precision in neuroscience. As novel therapeutics like psychedelics reshape the treatment landscape for psychiatric disease, platforms like Beacon’s will be critical for objectively measuring brain-based outcomes and accelerating development.”